Muscle

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Reference Values of Handgrip and Lower Extremity Strength for Vietnamese Men and Women: The Vietnam Osteoporosis Study.

Falls and sarcopenia are significant public health issues in Vietnam. Despite muscle strength being a critical predictor for these conditions, reference data on muscle strength within the Vietnamese population are lacking. To establish the reference ranges for muscle strength among...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreReference Values of Handgrip and Lower Extremity Strength for Vietnamese Men and Women: The Vietnam Osteoporosis Study.

Ergogenic Benefits of ฮฒ-Hydroxy-ฮฒ-Methyl Butyrate (HMB) Supplementation on Body Composition and Muscle Strength: An Umbrella Review of Meta-Analyses.

ฮฒ-Hydroxy-ฮฒ-methyl butyrate (HMB) is a metabolite of the amino acid leucine, known for its ergogenic effects on body composition and strength. Despite these benefits, the magnitude of these effects remains unclear due to variability among studies. This umbrella review aims...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreErgogenic Benefits of ฮฒ-Hydroxy-ฮฒ-Methyl Butyrate (HMB) Supplementation on Body Composition and Muscle Strength: An Umbrella Review of Meta-Analyses.

C-Terminal Agrin Fragment as a Biomarker for Sarcopenia: A Systematic Review and Meta-Analysis.

Sarcopenia is a gradual decline in skeletal muscle mass and strength, which eventually leads to reduced physical performance. 50% of people aged 60-80โ€‰years suffer from sarcopenia. Considering the devastating outcomes and the importance of promoting healthy ageing, the diagnosis and...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreC-Terminal Agrin Fragment as a Biomarker for Sarcopenia: A Systematic Review and Meta-Analysis.

Local Inflammation Precedes Diaphragm Wasting and Fibrotic Remodelling in a Mouse Model of Pancreatic Cancer.

Cancer cachexia represents a debilitating muscle wasting condition that is highly prevalent in gastrointestinal cancers, including pancreatic ductal adenocarcinoma (PDAC). Cachexia is estimated to contribute to ~30% of cancer-related deaths, with deterioration of respiratory muscles suspected to be a key...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreLocal Inflammation Precedes Diaphragm Wasting and Fibrotic Remodelling in a Mouse Model of Pancreatic Cancer.

Sheer drop ahead: reviewing sarcopenia outcomes in elderly patients undergoing bariatric surgery.

The global prevalence of obesity among elderly patients continues to rise. Despite the availability of new antiobesity medications, bariatric surgery remains an effective treatment option for carefully selected candidates. However, it is not risk-free, especially in a vulnerable population, predisposing...

๐Ÿ—“๏ธ 2025-02-08
๐Ÿ“ฐ Publication: Reviews In Endocrine & Metabolic Disorders
Read MoreSheer drop ahead: reviewing sarcopenia outcomes in elderly patients undergoing bariatric surgery.

Characterization of SARS-CoV-2 Entry Genes in Skeletal Muscle and Impacts of Inย Vitro Versus Inย Vivo Infection.

COVID-19 has been associated with both respiratory (diaphragm) and non-respiratory (limb) muscle atrophy. It is unclear if SARS-CoV-2 infection of skeletal muscle plays a role in these changes. This study sought to: 1) determine if cells comprising skeletal muscle tissue,...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreCharacterization of SARS-CoV-2 Entry Genes in Skeletal Muscle and Impacts of Inย Vitro Versus Inย Vivo Infection.

Transcriptomic Profiling Reveals 17ฮฒ-Estradiol Treatment Represses Ubiquitin-Proteasomal Mediators in Skeletal Muscle of Ovariectomized Mice.

With a decline of 17ฮฒ-estradiol (E2) at menopause, E2 has been implicated in the accompanied loss of skeletal muscle mass and strength. We aimed at characterizing transcriptomic responses of skeletal muscle to E2 in female mice, testing the hypothesis that...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTranscriptomic Profiling Reveals 17ฮฒ-Estradiol Treatment Represses Ubiquitin-Proteasomal Mediators in Skeletal Muscle of Ovariectomized Mice.

Descriptive Epidemiology and Prognostic Significance of Diaphragm Thickness in the General Population: The Nagahama Study.

Diaphragm thickness is a potential marker of sarcopenia in addition to muscle mass and strength at extremities. We aimed to clarify the descriptive epidemiology and prognostic significance of diaphragm thickness in the general population. The study participants were 3324 community...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreDescriptive Epidemiology and Prognostic Significance of Diaphragm Thickness in the General Population: The Nagahama Study.

Novel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-ฮบB signaling and oxidative stress.

Cancer-associated cachexia (CAC) is a severe metabolic disorder syndrome mainly characterized by muscle and fat loss, which accounts for one-third of cancer-related deaths. No effective therapeutic approach that could fully reverse CAC is available. NF-ฮบB signaling and oxidative stress play...

๐Ÿ—“๏ธ 2024-04-08
๐Ÿ“ฐ Publication: Genes & Diseases
Read MoreNovel oral compound Z526 mitigates cancer-associated cachexia via intervening NF-ฮบB signaling and oxidative stress.

Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions.

Sarcopenia is defined as a muscle-wasting syndrome that occurs with accelerated aging, while cachexia is a severe wasting syndrome associated with conditions such as cancer and immunodeficiency disorders, which cannot be fully addressed through conventional nutritional supplementation. Sarcopenia can be...

๐Ÿ—“๏ธ 2025-01-05
Read MoreSarcopenia and cachexia: molecular mechanisms and therapeutic interventions.

Norharmane prevents muscle aging via activation of SKN-1/NRF2 stress response pathways.

Sarcopenia, the age-related decline in muscle mass and function, is a significant contributor to increased frailty and mortality in the elderly. Currently, no FDA-approved treatment exists for sarcopenia. Here, we identified norharmane (NR), a ฮฒ-carboline alkaloid, as a potential therapeutic...

๐Ÿ—“๏ธ 2025-01-27
๐Ÿ“ฐ Publication: Redox Biology
Read MoreNorharmane prevents muscle aging via activation of SKN-1/NRF2 stress response pathways.

Why are we not exploring the potential of lower limb muscle power to identify people with sarcopenia?

Sarcopenia refers to a neuromuscular disease characterized by age-related declines in muscle mass and function. Since Professor Rosenberg first introduced the concept of sarcopenia in 1989, numerous operational paradigms have been proposed, tested, and validated against negative outcomes. The most...

๐Ÿ—“๏ธ 2025-01-14
๐Ÿ“ฐ Publication: Ageing Research Reviews
Read MoreWhy are we not exploring the potential of lower limb muscle power to identify people with sarcopenia?

Body composition alterations in patients with lung cancer.

Most patients with lung cancer experience cancer cachexia (CC), a syndrome of skeletal muscle and adipose tissue wasting. Knowledge of body composition changes in patients is limited, however, because most studies have been cross-sectional, comparing patients with non-cancer controls or...

๐Ÿ—“๏ธ 2025-01-31
๐Ÿ“ฐ Publication: American Journal Of Physiology-Cell Physiology
Read MoreBody composition alterations in patients with lung cancer.

Targeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches.

The skeletal muscle is one of the largest organs in the body and is responsible for the mechanical activity required for posture, movement and breathing. The effects of current pharmaceutical therapies for skeletal muscle diseases are far from satisfactory; approximately...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreTargeting Drug Delivery System to Skeletal Muscles: A Comprehensive Review of Different Approaches.

Multiomics Analysis Reveals Therapeutic Targets for Chronic Kidney Disease With Sarcopenia.

The presence of sarcopenia in patients with chronic kidney disease (CKD) is associated with poor prognosis. The mechanism underlying CKD-induced muscle wasting has not yet been fully explored. This study investigates the influence of renal secretions on muscles using multiomics...

๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMultiomics Analysis Reveals Therapeutic Targets for Chronic Kidney Disease With Sarcopenia.

Multi-omic profiling of sarcopenia identifies disrupted branched-chain amino acid catabolism as a causal mechanism and therapeutic target.

Sarcopenia is a geriatric disorder characterized by a gradual loss of muscle mass and function. Despite its prevalence, the underlying mechanisms remain unclear, and there are currently no approved treatments. In this study, we conducted a comprehensive analysis of the...

๐Ÿ—“๏ธ 2025-02-05
Read MoreMulti-omic profiling of sarcopenia identifies disrupted branched-chain amino acid catabolism as a causal mechanism and therapeutic target.

Muscle Wasting Disease (MWD) in Cachexia and Sarcopenia

Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form, it involves a significant lean body mass (including skeletal muscle), and fat loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/ mortality.

Two common but distinct conditions characterized by a loss of skeletal muscle mass are sarcopenia and cachexia. Sarcopenia, cachexia, and anorexic disorders (protein-energy malnutrition) represent the major causes of muscle-wasting disorders.

It has been known for millennia that muscle and fat wasting leads to poor outcomes including deaths in chronic disease states.

It is usually accompanied by physical inactivity, decreased mobility, slow gait, and poor physical endurance which are also common features of the frailty syndrome.

Fig. 1 โ€“ Framework for the suggested classification of MWD by disease etiology and disease progression.

Both cachexia and sarcopenia are characterized by an important muscle dysfunction that leads to increased morbidity and mortality.

Fig. 2 โ€“ The cachexia/ sarcopenia pyramid. Both lead to muscle dysfunction.

References

Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP.ย Why cachexia kills: examining the causality of poor outcomes in wasting conditions.ย J Cachexia Sarcopenia Muscle 2013; 4: 89โ€“94.

Evans WJ, Morley JE, Argilรฉs J, Bales C, Baracos V, Guttridge D, et al.ย Cachexia: a new definition.ย Clin Nutr 2008; 27: 793โ€“799.

Anker SD, Coats AJS, Morley JE, Rosano G, Bernabei R, Haehling S, et al.ย Muscle wasting disease: a proposal for a new disease classification.ย J Cachexia Sarcopenia Muscle 2014; 5: 1โ€“3.

Argiles JM, Busquets S, Stemmler B, Lรณpez-Soriano FJ.ย Cachexia and sarcopenia: mechanisms and potential targets for intervention.ย Current Opinion in Pharmacology 2015; 22: 100โ€“106.

Bowen TS, Schuler G, Adams V.ย Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training.ย J Cachexia Sarcopenia Muscle 2015; 6: 197โ€“207.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!